ContraFect (CFRX)
NASDAQ:CFRX

ContraFect Stock Analysis & Ratings

ContraFect Stock Analysis Overview

Smart Score
3
Underperform
1
2
3
4
5
6
7
8
9
10
Learn more about TipRanks Smart Score
The ContraFect stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.

Stock Chart

CFRX

CFRX Stock Stats

Previous Close$2.34
Open$2.37
Bid2.18 x 200
Ask2.86 x 300
Today’s Range$2.23 - $2.58
52-Week Range$2.11 - $7.63
Volume124.81K
Average Volume185.05K
Market Cap$97.94M
Beta0.76
P/E Ratio-3.7
EPS-0.68
Earnings DateMar 17, 2022

Company Description

ContraFect

ContraFect Corp. is a clinical stage biotechnology company , which engages in discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases. Its pipeline consists of CF-301, a bacteriophage-derived lysin with potent activity against Staphylococcus aureus bloodstream infections; and CF-404, which composed of three fully human monoclonal antibodies designed to treat all seasonal strains of human influenza. The company was founded by Robert Nowinski on March 5, 2008 and is headquartered in Yonkers, NY.
Sector
Healthcare
Industry
Biotechnology
CEO
Roger J. Pomerantz
Employees
33
Website
www.contrafect.com
ISIN
US2123263004
Address
28 Wells Avenue, Yonkers, NY, 10701, US

Financials


P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

CFRX FAQ

What was ContraFect’s price range in the past 12 months?
ContraFect lowest stock price was $2.11 and its highest was $7.63 in the past 12 months.
    What is ContraFect’s market cap?
    ContraFect’s market cap is $97.94M.
      What is ContraFect’s price target?
      The average price target for ContraFect is $11.50. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $14.00 ,the lowest forecast is $9.00. The average price target represents 361.85% Increase from the current price of $2.49.
        What do analysts say about ContraFect?
        ContraFect’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
          When is ContraFect’s upcoming earnings report date?
          ContraFect’s upcoming earnings report date is Mar 17, 2022 which is in 49 days.
            How were ContraFect’s earnings last quarter?
            ContraFect released its earnings results on Nov 15, 2021. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.192 by $0.062.
              Is ContraFect overvalued?
              According to Wall Street analysts ContraFect’s price is currently Undervalued.
                Does ContraFect pay dividends?
                ContraFect does not currently pay dividends.
                What is ContraFect’s EPS estimate?
                ContraFect’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does ContraFect have?
                ContraFect has 39,330,000 shares outstanding.
                  What happened to ContraFect’s price movement after its last earnings report?
                  ContraFect reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.192. Following the earnings report the stock price went down -15.942%.
                    Which hedge fund is a major shareholder of ContraFect?
                    Among the largest hedge funds holding ContraFect’s share is Oracle Investment Management Inc. It holds ContraFect’s shares valued at 7M.

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis